We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Gubra

News List

Boehringer Ingelheim, Gubra to validate new Peptides for obesity pharmaceutical-business-review
March 05, 2021
Boehringer Ingelheim has entered into a new research and licensing agreement with biotech company Gubra to identify and validate innovative peptides to treat obesity.
Boehringer Ingelheim, Gubra collaborate for the development of anti-obesity peptide poly-agonists biospectrumasia
June 05, 2019
Gubra may receive up to EUR 240 million in upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales
Boehringer collaborates with Gubra to develop next generation obesity treatments biospectrumasia
September 12, 2017
As per the deal, Boehringer can access Gubra’s expertise in the design, synthesis and preclinical testing of therapeutic peptides
Boehringer and Gubra collaborate to discover peptide compounds for obesity treatment pharmaceufical-technology
September 11, 2017
Germany-based Boehringer Ingelheim has entered a collaboration and licensing agreement with Danish biotech company Gubra to develop new peptide compounds to treat obesity.